T1	p 87 123	in healthy adults ?60 years of age .
T2	p 161 167	herpes
T3	p 227 228	,
T4	p 298 303	virus
T5	p 306 309	VZV
T6	p 507 538	with 210 subjects ?60 years old
T7	p 1122 1136	prevaccination
T8	p 1674 1696	adults ?60 years old .
T9	i 72 78	zoster
T10	i 298 305	virus (
T11	i 326 347	zoster vaccine ( ZV )
T12	i 448 450	ZV
T13	i 604 606	ZV
T14	i 636 643	placebo
T15	i 681 754	VZV interferon-gamma ( IFN-? ) enzyme-linked immunospot ( ELISPOT ) assay
T16	i 759 803	VZV glycoprotein enzyme-linked immunosorbent
T17	i 815 824	gpELISA )
T18	i 893 916	Vaccination Report Card
T19	i 973 986	IFN-? ELISPOT
T20	i 1019 1031	spot-forming
T21	i 1122 1136	prevaccination
T22	i 1304 1311	placebo
T23	i 1500 1507	placebo
T24	i 1567 1592	IFN-? ELISPOT and gpELISA
T25	i 1623 1625	ZV
T26	i 1714 1716	ZV
T27	i 1750 1755	boost
T28	o 6 48	Safety , tolerability , and immunogenicity
T29	o 149 167	severity of herpes
T30	o 180 181	)
T31	o 269 277	immunity
T32	o 377 395	protection against
T33	o 557 576	and safety profiles
T34	o 646 660	Immunogenicity
T35	o 685 711	interferon-gamma ( IFN-? )
T36	o 726 814	immunospot ( ELISPOT ) assay and VZV glycoprotein enzyme-linked immunosorbent antibody (
T37	o 831 860	. Adverse experiences ( AEs )
T38	o 912 918	Card .
T39	o 930 957	serious vaccine-related AEs
T40	o 967 1041	. VZV IFN-? ELISPOT geometric mean count ( GMC ) of spot-forming cells per
T41	o 1051 1085	peripheral blood mononuclear cells
T42	o 1243 1248	, GMC
T43	o 1356 1377	peak ELISPOT response
T44	o 1421 1462	gpELISA geometric mean titers ( GMTs ) in
T45	o 1563 1599	the IFN-? ELISPOT and gpELISA assays
T46	o 1640 1670	well-tolerated and immunogenic
T47	o 1731 1735	safe
T48	o 1785 1791	levels
T49	o 1801 1809	postdose